Catechin averts experimental diabetes mellitus-induced vascular endothelial structural and functional abnormalities

Cardiovascular Toxicology

Volumn 14, Issue 1, 2014, Pages 41-51

  Bhardwaj, Pooja ^a   Khanna, Deepa ^a   Balakumar, Pitchai ^b  

^a Rajendra Institute of Technology and Sciences   (India)

^b AIMST UNIVERSITY   (Malaysia)

Author keywords

Catechin hydrate; Diabetes mellitus; eNOS; Nitric oxide; Oxidative stress; PI3K; Vascular endothelial abnormalities

Indexed keywords

CATECHIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLUCOSE; NITRATE; NITRITE; PHOSPHATIDYLINOSITOL 3 KINASE; SUPEROXIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; ENZYME BLOOD LEVEL; ENZYME MECHANISM; EXPERIMENTAL DIABETES MELLITUS; EXPERIMENTAL VASCULAR ENDOTHELIAL ABNORMALITY; FEMALE; GLUCOSE BLOOD LEVEL; HYPERGLYCEMIA; LIPID PEROXIDATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION; TREATMENT DURATION; VASCULAR RING;

RATTUS;

ANIMALS; AORTA; BLOOD GLUCOSE; CATECHIN; CYTOPROTECTION; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; FEMALE; LIPID PEROXIDATION; NITRATES; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; NITRITES; OXIDATIVE STRESS; PHOSPHATIDYLINOSITOL 3-KINASE; RATS; RATS, WISTAR; SUPEROXIDES; VASODILATION; VASODILATOR AGENTS;

EID: 84895813974     PISSN: 15307905     EISSN: 15590259     Source Type: Journal    
DOI: 10.1007/s12012-013-9226-y     Document Type: Article

References (58)

1. http://www.idf.org/media-events/press-releases/2011/diabetes-atlas-5th- edition. Last Accessed on June17, 2013.
2. Salsali, A.; Nathan, M. (2006). A review of types 1 and 2 diabetes mellitus and their treatment with insulin. American Journal of Therapeutics, 13, 349-361.
3. Balakumar, P.; Dhanaraj, S. A. (2013). Cardiovascular pleiotropic actions of DPP-4 inhibitors: A step at the cutting edge in understanding their additional therapeutic potentials. Cellular Signalling, 25, 1799-1803.
4. Cooper, M. E.; Bonnet, F.; Oldfield, M.; Jandeleit-Dahm, K. (2001). Mechanisms of diabetic vasculopathy: An overview. American Journal of Hypertension, 14, 475-486.
5. Srinivasan, S.; Hatley, M. E.; Bolick, D. T.; Palmer, L. A.; Edelstein, D.; Brownlee, M.; et al. (2004). Hyperglycaemia-induced superoxide production decreases eNOS expression via AP-1 activation in aortic endothelial cells. Diabetologia, 47, 1727-1734.
6. Lee, H. Y.; Youn, S. W.; Oh, B. H.; Kim, H. S. (2012). Krüppel-like factor 2 suppression by high glucose as a possible mechanism of diabetic vasculopathy. Korean Circulation Journal, 42, 239-245.
7. Galley, H. F.; Webster, N. R. (2004). Physiology of the endothelium. British Journal of Anaesthesia, 93, 105-113.
8. Furchgott, R. F.; Zawadzki, J. V. (1980). The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature, 288, 373-376.
9. Ignarro, L. J.; Buga, G. M.; Wood, K. S.; Byrns, R. E.; Chaudhuri, G. (1987). Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proceedings of the National Academy of Sciences of the United States of America, 84, 9265-9269.
10. Forstermann, U.; Munzel, T. (2006). Endothelial nitric oxide synthase in vascular disease: From marvel to menace. Circulation, 113, 1708-1714.
11. Balakumar, P.; Kaur, T.; Singh, M. (2008). Potential target sites to modulate vascular endothelial dysfunction: Current perspectives and future directions. Toxicology, 245, 49-64.
12. Dimmeler, S.; Fleming, I.; Fisslthaler, B.; Hermann, C.; Busse, R.; Zeiher, A. M. (1999). Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation. Nature, 399, 601-605.
13. Bian, K.; Doursout, M. F.; Murad, F. (2008). Vascular system: Role of nitric oxide in cardiovascular diseases. Journal of Clinical Hypertension (Greenwich), 10, 304-310.
14. De Caterina, R.; Libby, P.; Peng, H. B.; Thannickal, V. J.; Rajavashisth, T. B.; Gimbrone, M. A.; Jr, et al. (1995). Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. Journal of Clinical Investigation, 96, 60-68.
15. Hadi, H. A. R.; Carr, C. S.; Al Suwaidi, J. (2005). Endothelial dysfunction: Cardiovascular risk factors, therapy, and outcome. Vascular Health and Risk Management, 1, 183-198.
16. Kathuria, S.; Mahadevan, N.; Balakumar, P. (2013). Possible involvement of PPARγ-associated eNOS signaling activation in rosuvastatin-mediated prevention of nicotine-induced experimental vascular endothelial abnormalities. Molecular and Cellular Biochemistry, 374, 61-72.
17. Taneja, G.; Mahadevan, N.; Balakumar, P. (2013). Fish oil blunted nicotine-induced vascular endothelial abnormalities possibly via activation of PPARγ-eNOS-NO signals. Cardiovascular Toxicology, 13, 110-122.
18. Kobayashi, T.; Matsumoto, T.; Kamata, K. (2005). The PI3-K/Akt pathway: Roles related to alterations in vasomotor responses in diabetic model. Journal of Smooth Muscle Research, 41, 283-302.
19. Kobayashi, T.; Taguchi, K.; Yasuhiro, T.; Matsumoto, T.; Kamata, K. (2004). Impairment of PI3-K/Akt pathway under lies attenuated endothelial function in aorta of type2 diabetic mouse model. Hypertension, 44, 956-962.
20. Taguchi, K.; Kobayashi, T.; Takenouchi, Y.; Matsumoto, T.; Kamata, K. (2011). Angiotensin II causes endothelial dysfunction via the GRK2/Akt/eNOS pathway in aortas from a murine type 2 diabetic model. Pharmacological Research, 64, 535-546.
21. Pricci, F.; Leto, G.; Amadio, L.; Iacobini, C.; Cordone, S.; Catalano, S.; et al. (2003). Oxidative stress in diabetes-induced endothelial dysfunction involvement of nitricoxide and protein kinase C. Free Radical Biology & Medicine, 35, 683-694.
22. Giugliano, D.; Ceriello, A.; Paolisso, G. (1996). Oxidative stress and diabetic vascular complications. Diabetes Care, 19, 257-267.
23. Sang, S.; Lambert, J. D.; Ho, C. T.; Yang, C. S. (2011). The chemistry and biotransformation of tea constituents. Pharmacological Research, 64, 87-99.
24. Islam, M. A. (2012). Cardiovascular effects of green tea catechins: Progress and promise. Recent Patents on Cardiovascular Drug Discovery, 7, 88-99.
25. Babu, P. V.; Liu, D. (2008). Green tea catechins and cardiovascular health: An update. Current Medicinal Chemistry, 15, 1840-1850.
26. Higdon, J. V.; Frei, B. (2003). Tea catechins and polyphenols: Health effects, metabolism, and antioxidant functions. Critical Reviews in Food Science and Nutrition, 43, 89-143.
27. Bharrhan, S.; Koul, A.; Chopra, K.; Rishi, P. (2011). Catechin suppresses an array of signaling molecules and modulates alcohol-induced endotoxin mediated liver injury in a rat model. PLoS ONE, 6, e20635.
28. Kim, M. J.; Rhee, S. J. (2004). Green tea catechins protect rats from microwave-induced oxidative damage to heart tissue. Journal of Medicinal Food, 7, 299-304.
29. Lorenz, M.; Wessler, S.; Follmann, E.; Michaelis, W.; Düsterhöft, T.; Baumann, G.; et al. (2004). A constituent of green tea, epigallocatechin-3-gallate, activates endothelial nitric oxide synthase by a phosphatidylinositol-3-OH-kinase-, cAMP-dependent protein kinase,- and Akt-dependent pathway and leads to endothelial-dependent vasorelaxation. Journal of Biological Chemistry, 279, 6190-6195.
30. Pieper, G. M.; Langenstroer, P.; Siebeneich, W. (1997). Diabetic-induced endothelial dysfunction in rat aorta: Role of hydroxyl radicals. Cardiovascular Research, 34, 145-156.
31. Balakumar, P.; Chakkarwar, V. A.; Singh, M. (2009). Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat. Molecular and Cellular Biochemistry, 320, 149-162.
32. Mittra, S.; Singh, M. (1998). Possible mechanism of captopril induced endothelium-dependent in isolated rabbit aorta. Molecular and Cellular Biochemistry, 183, 63-67.
33. Shah, D. I.; Singh, M. (2006). Effect of bis (maltolato) oxovanadium on experimental vascular endothelial dysfunction. Naunyn-Schmiedeberg's Archives of Pharmacology, 373, 221-229.
34. Sastry, K. V.; Moudgal, R. P.; Mohan, J.; Tyagu, J. S.; Rao, G. S. (2002). Spectrophotometric determination of serum nitrite and nitrate by copper-cadmium alloy. Analytical Biochemistry, 306, 79-82.
35. Kaur, J.; Reddy, K.; Balakumar, P. (2010). The novel role of fenofibrate in preventing nicotine- and sodium arsenite-induced vascular endothelial dysfunction in the rat. Cardiovascular Toxicology, 10, 227-238.
36. Kaur, T.; Goel, R. K.; Balakumar, P. (2010). Effect of rosiglitazone in sodium arsenite-induced experimental vascular endothelial dysfunction. Archives of Pharmacal Research, 33, 611-618.
37. Sena, C. M.; Matafome, P.; Crisóstomo, J.; Rodrigues, L.; Fernandes, R.; Pereira, P. (2012). Methylglyoxal promotes oxidative stress and endothelial dysfunction. Pharmacological Research, 65, 497-506.
38. Wang, H. D.; Pagano, P. J.; Du, Y.; Cayatte, A. J.; Quinn, M. T.; Brecher, P.; et al. (1998). Superoxide anion from the adventitia of the rat thoracic aorta inactivates nitric oxide. Circulation Research, 82, 810-818.
39. Kanie, N.; Kamata, K. (2002). Effects of chronic administration of the novel endothelin antagonist J-104132 on endothelial dysfunction in streptozotocin-induced diabetic rat. British Journal of Pharmacology, 135, 1935-1942.
40. Ma, F. X.; Liu, L. Y.; Xiong, X. M. (2003). Protective effects of lovastatin on vascular endothelium injured by low density lipoprotein. Acta PharmacologicaSinica, 24, 1027-1032.
41. Cai, H.; Harrison, D. G. (2000). Endothelial dysfunction in cardiovascular diseases: The role of oxidant stress. Circulation Research, 87, 840-844.
42. Puddu, P.; Puddu, G. M.; Zaca, F.; Muscari, A. (2000). Endothelial dysfunction in hypertension. Acta Cardiologica, 55, 221-232.
43. Hirase, T.; Node, K. (2012). Endothelial dysfunction as a cellular mechanism for vascular failure. American Journal of Physiology. Heart and Circulatory Physiology, 302, H499-H505.
44. Shah, D. I.; Singh, M. (2006). Activation of protein kinase A improves vascular endothelial dysfunction. Endothelium, 13, 267-277.
45. Sena, C. M.; Matafome, P.; Louro, T.; Nunes, E.; Fernandes, R.; Seiça, R. M. (2011). Metformin restores endothelial function in aorta of diabetic rats. British Journal of Pharmacology, 163, 424-437.
46. Cheng, F.; Wang, Y.; Li, J.; Su, C.; Wu, F.; Xia, W. H.; et al. (2012). Berberine improves endothelial function by reducing endothelial microparticles-mediated oxidative stress in humans. International Journal of Cardiology. doi: 10.1016/j.ijcard.2012.03.090.
47. Higashi, Y.; Noma, K.; Yoshizumi, M.; Kihara, Y. (2009). Endothelial function and oxidative stress in cardiovascular diseases. Circulation Journal, 73, 411-418.
48. Ohkawa, H.; Ohishi, N.; Yagi, K. (1979). Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Analytical Biochemistry, 95, 351-358.
49. Miller, F. J, Jr, Gutterman, D. D.; Rios, C. D.; Heistad, D. D.; Davidson, B. L. (1998). Superoxide production in vascular smooth muscle contributes to oxidative stress and impaired relaxation in atherosclerosis. Circulation Research, 82, 1298-1305.
50. Balakumar, P.; Sharma, R.; Singh, M. (2008). Benfotiamine attenuates nicotine and uric acid-induced vascular endothelial dysfunction in the rat. Pharmacological Research, 58, 356-363.
51. Akar, F.; Pektas, M. B.; Tufan, C.; Soylemez, S.; Sepici, A.; Ulus, A. T.; et al. (2011). Resveratrol shows vasoprotective effect reducing oxidative stress without affecting metabolic disturbances in insulin-dependent diabetes of rabbits. Cardiovascular Drugs and Therapy, 25, 119-131.
52. Meyrelles, S. S.; Peotta, V. A.; Pereira, T. M.; Vasquez, E. C. (2011). Endothelial dysfunction in the apolipoprotein E-deficient mouse: Insights into the influence of diet, gender and aging. Lipids in Health and Disease, 10, 211.
53. Sena, C. M.; Nunes, E.; Louro, T.; Proença, T.; Fernandes, R.; Boarder, M. R.; et al. (2008). Effects of alpha-lipoic acid on endothelial function in aged diabetic and high-fat fed rats. British Journal of Pharmacology, 153, 894-906.
54. Conners, W.; Whitebeck, C.; Chicester, P.; Legget, R.; Lin, A. D.; Johnson, A.; et al. (2006). L-NAME, a nitricoxide synthase inhibitor, diminishes oxidative damage in urinary bladder partial outlet obstruction. Renal Physiology: American Journal of Physiology, 290, F357-F363.
55. Yang, A. L.; Chao, J. I.; Lee, S. D. (2007). Altered insulin-mediated and insulin-like growth factor-1-mediated vasorelaxation in aortas of obese Zucker rats. International Journal of Obesity (London), 31, 72-77.
56. Powis, G.; Bonjouklian, R.; Berggren, M. M.; Gallegos, A.; Abraham, R.; Ashendel, C.; et al. (1994). Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3-kinase. Cancer Research, 54, 2419-2423.
57. Ferro, A.; Coash, M.; Yamamoto, T.; Rob, J.; Ji, Y.; Queen, L. (2004). Nitric oxide-dependent beta2-adrenergic dilatation of rat aorta is mediated through activation of both protein kinase A and Akt. British Journal of Pharmacology, 143, 397-403.
58. Hase, M.; Babazono, T.; Karibe, S.; Kinae, N.; Iwamoto, Y. (2006). Reno protective effects of tea catechin in streptozotocin- induced diabetic rats. International Urology and Nephrology, 38, 693-699.